Levetiracetam Pediatric Dose — Anticonvulsant
Levetiracetam is a broad-spectrum anticonvulsant that modulates synaptic vesicle protein SV2A to reduce abnormal neuronal firing. It is widely used in pediatric practice for the acute management and maintenance treatment of seizures, including status epilepticus and focal or generalized epilepsy syndromes. Its favorable pharmacokinetic profile and availability in both IV and oral formulations make it a practical choice across a wide range of clinical settings.
Pediatric Dosing
| Phase | Dose | Route | Frequency |
|---|---|---|---|
| Loading | 20–30 mg/kg/dose | IV | Once |
| Initial Maintenance | 10 mg/kg/dose | IV or PO | Every 12 hours |
| Titrated Maintenance | 10–30 mg/kg/dose | IV or PO | Every 12 hours |
Maintenance doses are typically initiated at 10 mg/kg/dose every 12 hours and titrated upward based on clinical response to a maximum of 30 mg/kg/dose every 12 hours. Consult institutional protocol for absolute maximum single-dose and total daily dose ceilings.
Worked example (20 kg child): Loading dose at 20 mg/kg = 20 × 20 mg/kg = 400 mg IV (or up to 20 × 30 mg/kg = 600 mg IV). Initial maintenance at 10 mg/kg = 20 × 10 mg/kg = 200 mg IV/PO every 12 hours.
Indications and Clinical Context
Levetiracetam is indicated for the management of pediatric seizures, including as second-line therapy for status epilepticus when benzodiazepines have failed, consistent with PALS and Neurocritical Care Society guidelines. Its IV formulation allows rapid administration in the acute setting, while seamless conversion to oral dosing supports long-term maintenance therapy.
The loading dose strategy is primarily employed in the acute or emergent seizure setting to rapidly achieve therapeutic plasma concentrations. Ongoing maintenance dosing is titrated to seizure control and tolerability, making levetiracetam a versatile agent for both inpatient and outpatient pediatric neurology management.
Administration and Monitoring
The IV loading dose should be infused over 15 minutes; more rapid administration is not recommended due to the risk of adverse cardiovascular and CNS effects. Oral and IV doses are considered bioequivalent, facilitating straightforward route transitions. Renal dose adjustment is required in patients with impaired creatinine clearance, as levetiracetam is predominantly renally eliminated.
- Route: IV infusion or oral (tablet, solution)
- Loading infusion: Administer over 15 minutes IV
- Adverse effects to monitor: Somnolence, irritability, behavioral changes, and dizziness
- Key consideration: No significant hepatic metabolism; minimal drug-drug interactions compared with other anticonvulsants
- Max dose: Consult institutional protocol for weight-based daily dose ceiling
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.